Literature DB >> 19128272

Evaluation and treatment of resistant or difficult-to-control hypertension.

David Wojciechowski1, Vasilios Papademetriou, Charles Faselis, Ross Fletcher.   

Abstract

An observational study was conducted in 164 patients with resistant or difficult-to-control hypertension. Treatment was adjusted to achieve blood pressure recommendations from the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). Patients were mostly male (95.73%) and African American (86.59%) and had an average age of 63.68 years. Comorbidities included diabetes (42.07%) and chronic kidney disease, with an average estimated glomerular filtration rate of 83.55 mL/min/1.73 m(2). At the time of referral, average blood pressure was 160/87 mm Hg. The average number of antihypertensive medications per patient at baseline was 3.43, which increased to 4.06 and 4.18 at 3 and 6 months, respectively (P< or =.0008), with about 80% of patients receiving a diuretic prior to intervention. Blood pressure decreased to 135.55/74.55 and 137.62/74.03 mm Hg at 3 and 6 months, respectively (P<.0001). By month 6, the blood pressure goal was reached in 45.10% of patients. At months 3 and 6, 100% of patients were now receiving a diuretic. The average estimated glomerular filtration rate at month 6 was 79.36 mL/min/1.73 m(2) (P=NS). Patients referred for resistant or difficult-to-control hypertension may be controlled by making targeted adjustments to their medical regimen.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19128272      PMCID: PMC8673237          DOI: 10.1111/j.1751-7176.2008.00037.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  26 in total

1.  Management of hypertension. Clinical and hemodynamic studies with special reference to patients refractory to treatment.

Authors:  O Andersson
Journal:  Acta Med Scand Suppl       Date:  1977

2.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

Review 3.  Resistant hypertension.

Authors:  David A Calhoun; Mohammad A Zaman; Mari K Nishizaka
Journal:  Curr Hypertens Rep       Date:  2002-06       Impact factor: 5.369

4.  National Ambulatory Medical Care Survey: 2000 summary.

Authors:  Donald K Cherry; David A Woodwell
Journal:  Adv Data       Date:  2002-06-05

5.  Plasma volume in resistant hypertension: guide to pathophysiology and therapy.

Authors:  J W Graves; R L Bloomfield; V M Buckalew
Journal:  Am J Med Sci       Date:  1989-12       Impact factor: 2.378

6.  The burden of adult hypertension in the United States 1999 to 2000: a rising tide.

Authors:  Larry E Fields; Vicki L Burt; Jeffery A Cutler; Jeffrey Hughes; Edward J Roccella; Paul Sorlie
Journal:  Hypertension       Date:  2004-08-23       Impact factor: 10.190

Review 7.  Lessons on the interaction of race and antihypertensive drugs from the VA cooperative study group on antihypertensive agents.

Authors:  B J Materson
Journal:  Am J Hypertens       Date:  1995-12       Impact factor: 2.689

8.  Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

Authors:  David A Calhoun; Daniel Jones; Stephen Textor; David C Goff; Timothy P Murphy; Robert D Toto; Anthony White; William C Cushman; William White; Domenic Sica; Keith Ferdinand; Thomas D Giles; Bonita Falkner; Robert M Carey
Journal:  Circulation       Date:  2008-06-24       Impact factor: 29.690

9.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

10.  [Compliance problems in therapy resistant hypertension].

Authors:  Bernd-Christoph Werlemann; Elmar Offers; Rainer Kolloch
Journal:  Herz       Date:  2004-05       Impact factor: 1.443

View more
  3 in total

1.  Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial.

Authors:  Murray D Esler; Michael Böhm; Horst Sievert; Christian L Rump; Roland E Schmieder; Henry Krum; Felix Mahfoud; Markus P Schlaich
Journal:  Eur Heart J       Date:  2014-06-04       Impact factor: 29.983

2.  Renal Sympathetic Denervation for the Treatment of Difficult-to-Control or Resistant Hypertension.

Authors:  Vasilios Papademetriou; Michalis Doumas; Konstantinos Tsioufis
Journal:  Int J Hypertens       Date:  2011-03-30       Impact factor: 2.420

3.  Difficult-to-Treat or Resistant Hypertension: Etiology, Pathophysiology, and Innovative Therapies.

Authors:  Vasilios Papademetriou; Konstantinos Tsioufis; Alan Gradman; Henry Punzi
Journal:  Int J Hypertens       Date:  2011-06-01       Impact factor: 2.420

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.